<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lai TC</submitter><funding>Ministry of Science and Technology, Taiwan</funding><funding>Academia Sinica</funding><pagination>164</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7579951</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Chemotherapy is currently one of the most effective treatments for advanced breast cancer. Anti-microtubule agents, including taxanes, eribulin and vinca-alkaloids are one of the primary major anti-breast cancer chemotherapies; however, chemoresistance remains a problem that is difficult to solve. We aimed to discover novel candidate protein targets to combat chemoresistance in breast cancer.&lt;h4>Methods&lt;/h4>A lentiviral shRNA-based high-throughput screening platform was designed and developed to screen the global kinome to find new therapeutic targets in paclitaxel-resistant breast cancer cells. The phenotypes were confirmed with alternative expression in vitro and in vivo. Molecular mechanisms were investigated using global phosphoprotein arrays and expression microarra</pubmed_abstract><journal>Cell communication and signaling : CCS</journal><pubmed_title>Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.</pubmed_title><pmcid>PMC7579951</pmcid><funding_grant_id>MOST 106-0210-01-15-02, MOST 107-0210-01-19-01</funding_grant_id><pubmed_authors>Yang YF</pubmed_authors><pubmed_authors>Chang PM</pubmed_authors><pubmed_authors>Liu CY</pubmed_authors><pubmed_authors>Fang CY</pubmed_authors><pubmed_authors>Jan YH</pubmed_authors><pubmed_authors>Hsiao M</pubmed_authors><pubmed_authors>Lai TC</pubmed_authors><pubmed_authors>Hsieh HL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.</name><description>&lt;h4>Background&lt;/h4>Chemotherapy is currently one of the most effective treatments for advanced breast cancer. Anti-microtubule agents, including taxanes, eribulin and vinca-alkaloids are one of the primary major anti-breast cancer chemotherapies; however, chemoresistance remains a problem that is difficult to solve. We aimed to discover novel candidate protein targets to combat chemoresistance in breast cancer.&lt;h4>Methods&lt;/h4>A lentiviral shRNA-based high-throughput screening platform was designed and developed to screen the global kinome to find new therapeutic targets in paclitaxel-resistant breast cancer cells. The phenotypes were confirmed with alternative expression in vitro and in vivo. Molecular mechanisms were investigated using global phosphoprotein arrays and expression microarra</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Oct</publication><modification>2026-07-16T07:09:57.033Z</modification><creation>2020-10-29T15:57:56Z</creation></dates><accession>S-EPMC7579951</accession><cross_references><pubmed>33087151</pubmed><doi>10.1186/s12964-020-00600-2</doi></cross_references></HashMap>